- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
Transcript
Are there any drug approvals that you’re keeping a close eye on for 2019?
So, for 2019, we have the potential for some new nonalcoholic fatty liver disease (NASH) drugs to be approved, and actually right now there’s nothing approved to treat NASH. This is a condition that affects up to 16 million Americans, and its associated with liver fat, liver inflammation, fibrosis, and it’s often associated with obesity and other concurrent conditions can be affected in patients with NASH. Again, nothing is proved to treat them but next year we could see 2 new drugs approved. 2020 there’s even more, there’s several drugs with different mechanisms in development for NASH. So, it’s going to be interesting to see how that market progresses over time.
As far as other drugs for 2019 we’re keeping an eye on, there’s going to be some new oral therapies for multiple sclerosis (MS) that are going to be competing in the market. So, Cladribine is a new oral drug. Then we have some competitors to Gilenya, so Gilenya is going to be going generic, but there are 2 new medications with similar mechanisms, which may have better safety profiles that could be approved. One of them, Siponimod, is for secondary progressive MS, which currently has no approved treatment therapies. So, those are just a few examples of key drugs to watch for next year.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
